Original Research Article

An observational cross-sectional study to determine the effect of telmisartan on reducing microalbuminuria in diabetic hypertensive patients in tertiary care teaching hospital, Central India

Santenna Chenchula¹*, Rupesh Gupta², Balakrishnan S.¹, Akash Vishwe¹, Pushparaj Gour¹, Sunil Kumar¹

¹Department of Pharmacology, ²Department of General Medicine, AIIMS, Bhopal, Madhya Pradesh, India

Received: 31 May 2017  
Revised: 02 July 2017  
Accepted: 05 July 2017  

*Correspondence to:  
Dr. Santenna Chenchula,  
Email: csanten7@gmail.com

ABSTRACT

Background: There are many groups of drugs to decrease microalbuminuria like angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), calcium channel blockers and direct vasodilators. Among these, ACEI and ARBs are commonly used for this purpose. If side effects occur, ACEI are replaced with ARBs. Many ARBs have been studied for their effect on reducing microalbuminuria, but data on telmisartan with its additional unique properties are scarce in Indian population.

Methods: This cross sectional observational study was carried out in a tertiary care centre. We first measured base line urine albumin levels in included patients, 3 months after treatment with telmisartan using ‘hemocue albumin analyser’. We collected and compared both baseline and after treatment data of microalbuminuria and analysed in descriptive statistics.

Results: A total of 110 patients participated in this study; out of which 10 patients were excluded from the study because they were not available for follow up. As compared to baseline, urine albumin level decreased by 30.42% after 12 weeks treatment with telmisartan (P <0.001).

Conclusions: Microalbuminuria is one of the leading cause of end stage renal disease and coronary heart diseases in diabetic hypertensive patients. Drugs like ACE inhibitors, Angiotensin receptor blockers, Calcium channel blockers and direct vasodilators are used to prevent these complications. In this present study, we concluded that telmisartan decreases urine albumin excretion around 30.42% from baseline after 12 weeks of treatment.

Keywords: Diabetic nephropathy, Microalbuminuria, Telmisartan

INTRODUCTION

Nephropathy is a frequent complication of diabetes, the most common cause of kidney failure in the western world, and results in decreased life expectancy. Diabetes mellitus (DM) is a metabolic disorder with different causes, characterized by hyperglycaemia resulting from defects in insulin secretion and / or action. In year 2000 171 million cases of DM worldwide were estimated and that number is expected to increase to 366 million cases in 2030.¹ Microalbuminuria is a subclinical increase in urinary albumin excretion. By definition it defined as an albumin excretion rate of 20 to 200milligram/Litre in the first morning sample, 20-200µg/min in a timed overnight or 24 hour sample on at least 2 of 3 occasions within a period of 6 months (or) an albumin to creatinine ratio (mg/mmol) of 2.5 to 25 in males and 3.5 to 35 in females.² Microalbuminuria is an important clinical finding because it is not only associated with an increased risk of progression to proteinuria (macroalbuminuria) and renal failure, but also increase risk for cardiovascular events. In patients who progress to nephropathy, microalbuminuria
usually precedes macroalbuminuria by an interval of 5 to 10 years. The increasing prevalence of DM has led to a growing number of chronic complications including diabetic nephropathy (DN). Approximately 30% of patients with either type 1 or type 2 DM develop DN. DN is the single most common cause of end stage renal disease (ESRD) in adults. The life time risk of developing DN with progression to ESRD is roughly same in type 1 and type 2 DM. The presence of DN indicates a marked increase in patient morbidity and premature mortality, and significantly impacts the cost of care. ESRD in those with Diabetes remains a significant predictor for increase in cardiovascular risk and mortality.

Diabetic nephropathy is characterized by a group of diabetic pathophysiological changes which begin with glomerular hyperfiltration and renal hypertrophy, and then progress to proteinuria and glomerular filtration rate reduction. As the molecular mechanisms leading to ESRD in DN are still unknown, treatment of DN becomes complex and the therapeutic goal is difficult to achieve.

The renin angiotensin system plays a predominant role in the renal disease evolution, not only by inducing changes in arterial pressure, glomerular physiology, but also by increasing oxidative stress through production of superoxide anion (O2·-) and hydroxyl radicals (‘OH). Uncontrolled hypertension also contributes to increases in proteinuria, and blood pressure control is associated with reduced urinary protein excretion and slowed decline in renal function. Achievement of a target blood pressure, that is, <140/90mm Hg in patients with proteinuria, using a blocker of the renin–angiotensin system as part of the regimen, is recommended by current guidelines.

Telmisartan is one of the angiotensin receptor blockers. Moreover, it acts as a partial agonist of peroxisome proliferator-activated receptor γ (PPAR γ). Recent evidence shows that telmisartan provides renal benefit at all stages of the renal pathology in patients with type 2 DM. It improves endothelial function in patients with normoalbuminuria and it delays the progression to nephropathy in patients with microalbuminuria.

In a recent trial it was shown that the effect of telmisartan on protein excretion in DN appears to be better than losartan. More vascular protective effects of telmisartan than losartan were associated with greater anti-inflammatory effects of telmisartan, as shown by attenuation of vascular nuclear factor kappa B (NFκB) activation and tumor necrosis factor factor (TNF-α). In the ONTARGET study, telmisartan provided similar cardiovascular protection in comparison to ramipril in patients with DM.

The study protocols were approved by the institutional human ethics committee of AIIMS, Bhopal. Written informed consent was obtained from all participants and guidelines of good clinical practice were followed.

Data was presented as Mean±SEM. Statistical analysis was performed using graph pad (Graph Pad, San Diego, CA, USA) prism software. Difference in albumin levels before and after 12 weeks treatment with telmisartan was statistically analyzed by paired t test (student t test). A value of P ≤ 0.005 was taken as significant.
Nephropathy is a major cause of illness and death in diabetes. Indeed, the excess mortality of diabetes occurs mainly in diabetic nephropathy and results in not only from end stage renal disease (ESRD) but also from cardiovascular disease, with the latter being particularly common in type 2 diabetic patients. Diabetic nephropathy is the single most common cause of ESRD in Europe, Japan and the United States with diabetic patients accounting for 25% to 45% of all patients enrolled in ESRD programs.20,22

Microalbuminuria is primarily a consequence of glomerular damage. Some tubular functions are also altered in diabetes, but B2-microglobulin excretion (a sensitive index of proximal tubular reabsorptive capacity) is usually normal in microalbuminuric patients (but not in those with advanced renal failure). Loss of electrical charge and especially disruption of the size-selectivity properties of the glomerular filter occur in diabetic renal disease. These may result from abnormal synthesis of heparin sulphate, the main glycosaminoglycans component of the basement membrane which normally plays a role in the maintenance of anionic sites and pore size.

Intraglomerular hypertension due to deregulation of glomerular vessels has also been demonstrated in experimental studies and is associated with the observed increase in glomerular hyperfiltration. This hemodynamic abnormality is compounded further by systemic hypertension which is common in diabetes (especially NIDD). Although the existence and severity of hypertension are potent determinants of the prognosis of diabetes with microalbuminuria it usually appears after, rather than before or simultaneously with elevated albumin excretion. Angiotensin II has been shown to promote superoxide generation through NADPH oxidase activation, independently of its systemic vasoconstriction ability. Oxidative stress induced by superoxide anion (O₂⁻) excessive formation is considered a major cause of vascular injury due to diabetes which leads to microalbuminuria. An excess of the superoxide anion causes vascular injury by the formation of cytotoxic secondary reactive oxygen species i.e. peroxynitrite (ONOO⁻) and hydroxyl radicals ('OH). Experimental studies have shown that excessive superoxide is produced in human aortic endothelial cells by prolonged exposure to high glucose, and in mouse kidney glomeruli by chronic hyperglycemia,23,24 Exposure of structural and circulating proteins to high glucose levels increases the rate of their non-enzymatic glycosylation, and this may contribute to the alteration in the barrier properties of the glomerular basement membrane. Isolated micro vessels preferentially take up glycosylated albumin by endocytosis, and glycosylation of endothelial components further enhances this take-up. Moreover, glycosylated proteins, including albumin, have been shown to undergo preferential transport across the glomerular membrane.
Telmisartan therapy has reduced its progression to diabetic nephropathy from microalbuminuria by its Renoprotective effects. It decreased around 35% from base line. Even blood pressure levels also came to controlled levels as it is an effective anti hypertensive drug. Among 100 patients around 90 patients were shown good response in their proteinuria levels by their reduced albumin levels in urine. The Mean urinary albumin in mg/l in the baseline pre-treatment group was 53.05 and 22.63 after 3 months. The mean difference observed between two groups was 30.42, and it was statistically significant (P ≤0.001).

However, the mechanism underlying this Renoprotective effect afforded by telmisartan involves different mechanisms. Recent experimental studies have shown that telmisartan attenuates oxidative stress by down regulating NADPH oxidase, a major superoxide-producing enzyme.25

And another study has shown that telmisartan treatment enhances serum Superoxide dismutase (SOD) activity and systemically reduces oxidative and nitrosative stress in patients with microalbuminuric patients. The increase in serum SOD activity by telmisartan treatment showed a correlation with the reduction of albuminuria in microalbuminuria patients.

Therefore, blockade of the angiotensin II signaling pathway via AT1 receptors is expected to reduce the superoxide - induced oxidative stress. Although all ARBs may share the anti-oxidative effects to some extent, there seems to be a difference. It is thought that telmisartan show its action through its strong binding affinity to AT1 receptors, the longest plasma half-life and the highest lipophilicity of currently available ARBs. Furthermore, the action of telmisartan as a partial agonist for peroxisome proliferator-activated receptor- γ probably contributes to inhibition of NADPH oxidase.12-14

Nitric oxide (NO) has an important role in maintaining renal vascular endothelial function involved in the regulation of urinary albumin excretion. A recent clinical study reported that blood NO levels were decreased in type 2 diabetic patients with overt diabetic nephropathy compared with non-diabetic control subjects. Consistent with this study another clinical study showed increased NO levels with telmisartan and improvement of vascular endothelial function after telmisartan treatment in type 2 diabetic patients by measuring flow-mediated vasodilatation.

Thus, the increase in circulating NO following the reduction of hyperglycemia-induced oxidative stress by telmisartan treatment is thought to contribute to Renoprotection.

ACKNOWLEDGEMENTS

Authors would like to thank the Department of Pathology, AIIMS, Bhopal and other staff in Medicine Department.

Funding: Funding sources from Department of pharmacology, AIIMS, Bhopal

Conflict of interest: None declared

Ethical approval: The study was approved by the Institutional Ethics Committee (IHEC-LOP/2015/IM0073)

REFERENCES


